Form 4 for ENTA ENANTA PHARMACEUTICALS INC
Accepted 2021-11-02 00:00:00 ET · period of report 2021-11-01 · accession 0001177648-21-000029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-11-02 | 2021-11-01 | ENTA | Adda Nathalie | SVP, Chief Medical Off | S - Sale+OE | $84.89 | -9,547 | 26.9K | -26% | -$810.4K |
| D | 2021-11-02 | 2021-11-01 | ENTA | Adda Nathalie | SVP, Chief Medical Off | M - OptEx | $48.52 | +9,547 | 36.5K | +35% | +$463.2K |
| D | 2021-11-02 | 2021-11-01 | ENTA | Adda Nathalie | SVP, Chief Medical Off | M - OptEx | $0.00 | -9,547 | 14.0K | -41% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-11-01 | S | D | 7,495 | $85.02 | 27,044 | D | — | — | (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $84.74 to $85.63, inclusive. |
| 2 | Common | Common Stock | 2021-11-01 | M | A | 9,547 | $48.52 | 36,491 | D | — | — | |
| 3 | Common | Common Stock | 2021-11-01 | S | D | 1,952 | $84.31 | 34,539 | D | — | — | (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $83.74 to $84.73, inclusive. |
| 4 | Common | Common Stock | 2021-11-01 | S | D | 100 | $86.21 | 26,944 | D | — | — | |
| 5 | Derivative | Stock Option (Right to Buy) | 2021-11-01 | M | D | 9,547 | $0.00 | 13,953 | D | $48.52 · — to 2027-11-17 | 9,547 Common Stock | (F4) The option, representing a right to purchase a total of 23,500 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 17, 2017). |